Botulinum Toxin in Children with Cerebral Palsy: An Update
02 May 2019
12 June 2019
04 September 2019 (online)
Injected in a muscle, the botulinum toxin causes localized and temporary paralysis by acting on the neuromuscular synapse. Currently, it is widely prescribed for the treatment of limb spasticity in children from the age of 2 years. Combined with rehabilitation and other treatments, it helps to progress in motor learning, promotes functional progression, and delays orthopaedic degradations.
Numerous randomized, placebo-controlled studies have shown efficacy in reducing spasticity, improving passive and active mobility, reducing pain, and improving upper limb comfort care. The side effects are rare and commonplace.
The injection technique is accessible after specific training and practice. The indication is better evaluated by a multidisciplinary team. A precise clinical evaluation, assisted by an instrumental analysis (videography, spatiotemporal parameters, kinematics, kinetics, and electromyography), makes it possible to determine the aims of the treatment and to evaluate the outcome.
The objective of this review is to present current evidence base and practices regarding the use of botulinum toxin in children with cerebral palsy.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
- 1 Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol 1949; 109 (1-2): 10-24
- 2 Meunier FA, Schiavo G, Molgó J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 2002; 96 (1-2): 105-113
- 3 Brochard S, Blajan V, Lempereur M. , et al. Determining the technical and clinical factors associated with pain for children undergoing botulinum toxin injections under nitrous oxide and anesthetic cream. Eur J Paediatr Neurol 2011; 15 (04) 310-315
- 4 Ben-Pazi H, Cohen A, Kroyzer N. , et al. Clown-care reduces pain in children with cerebral palsy undergoing recurrent botulinum toxin injections - a quasi-randomized controlled crossover study. PLoS One 2017; 12 (04) e0175028 . Doi: 10.1371/journal.pone.0175028. eCollection 2017.
- 5 Alter KE, Karp BI. Ultrasound guidance for botulinum neurotoxin chemodenervation procedures. Toxins (Basel) 2017; 10 (01) E18
- 6 Pitcher CA, Elliott CM, Panizzolo FA, Valentine JP, Stannage K, Reid SL. Ultrasound characterization of medial gastrocnemius tissue composition in children with spastic cerebral palsy. Muscle Nerve 2015; 52 (03) 397-403
- 7 Traitement médicamenteux de la spasticité, recommandations de bonne pratique. French Agency for Drugs Security 2011 http://ansm.sante.fr/var/ansm_site/storage/original/application/a79f07eee915181bc9ae4e506140cecb.pdf Accessed 25 June 2018.
- 8 Gonnade N, Lokhande V, Ajij M, Gaur A, Shukla K. Phenol versus botulinum toxin A injection in ambulatory cerebral palsy spastic diplegia: a comparative study. J Pediatr Neurosci 2017; 12 (04) 338-343
- 9 Juneja M, Jain R, Gautam A, Khanna R, Narang K. Effect of multilevel lower-limb botulinum injections & intensive physical therapy on children with cerebral palsy. Indian J Med Res 2017; 146 (Supplement): S8-S14
- 10 Barwood S, Baillieu C, Boyd R. , et al. Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000; 42 (02) 116-121
- 11 Baker R, Jasinski M, Maciag-Tymecka I. , et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002; 44 (10) 666-675
- 12 Bjornson K, Hays R, Graubert C. , et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics 2007; 120 (01) 49-58
- 13 Fazzi E, Maraucci I, Torrielli S, Motta F, Lanzi G. Factors predicting the efficacy of botulinum toxin-A treatment of the lower limb in children with cerebral palsy. J Child Neurol 2005; 20 (08) 661-666
- 14 Hawamdeh ZM, Ibrahim AI, Al-Qudah AA. Long-term effect of botulinum toxin (A) in the management of calf spasticity in children with diplegic cerebral palsy. Eura Medicophys 2007; 43 (03) 311-318
- 15 Lee LR, Chuang YC, Yang BJ, Hsu MJ, Liu YH. Botulinum toxin for lower limb spasticity in children with cerebral palsy: a single-blinded trial comparing dilution techniques. Am J Phys Med Rehabil 2004; 83 (10) 766-773
- 16 Bottos M, Benedetti MG, Salucci P, Gasparroni V, Giannini S. Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment. Dev Med Child Neurol 2003; 45 (11) 758-762
- 17 Hazneci B, Tan AK, Guncikan MN, Dincer K, Kalyon TA. Comparison of the efficacies of botulinum toxin A and Johnstone pressure splints against hip adductor spasticity among patients with cerebral palsy: a randomized trial. Mil Med 2006; 171 (07) 653-656
- 18 Papavasiliou AS, Rapidi CA, Filiopoulos C, Rizou C, Skouteli HN. Evaluation of a multimodal management of prematurity-related spasticity. Pediatr Neurol 2006; 35 (06) 400-407
- 19 Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998; 18 (03) 304-311
- 20 Koman LA, Brashear A, Rosenfeld S. , et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001; 108 (05) 1062-1071
- 21 Wang Y, Gao B. A dose-response relationship research on botulinum toxin type A local intramuscular injections of lower extremity spasticity in children with cerebral palsy. Childs Nerv Syst 2008; 24 (05) 545-547
- 22 Metaxiotis D, Siebel A, Doederlein L. Repeated botulinum toxin A injections in the treatment of spastic equinus foot. Clin Orthop Relat Res 2002; (394) 177-185
- 23 Pidcock FS. Botulinum toxin type A treatment in neurogenetic syndromes. Pediatr Rehabil 2005; 8 (04) 298-302
- 24 Kawamura A, Campbell K, Lam-Damji S, Fehlings D. A randomized controlled trial comparing botulinum toxin A dosage in the upper extremity of children with spasticity. Dev Med Child Neurol 2007; 49 (05) 331-337
- 25 Lowe K, Novak I, Cusick A. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2006; 48 (03) 170-175
- 26 Russo RN, Crotty M, Miller MD, Murchland S, Flett P, Haan E. Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial. Pediatrics 2007; 119 (05) e1149-e1158
- 27 Wallen M, O'Flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Arch Phys Med Rehabil 2007; 88 (01) 1-10
- 28 Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: randomized double-blind clinical trial. Eur J Paediatr Neurol 2016; 20 (04) 532-537
- 29 Eek MN, Himmelmann K. No decrease in muscle strength after botulinum neurotoxin-a injection in children with cerebral palsy. Front Hum Neurosci 2016; 10: 506 eCollection 2016
- 30 Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006; 21 (03) 189-192
- 31 Boulay C, Jacquemier M, Castanier E. , et al. Planovalgus foot deformity in cerebral palsy corrected by botulinum toxin injection in the peroneus longus: clinical and radiological evaluations in young children. Ann Phys Rehabil Med 2015; 58 (06) 316-321
- 32 Sutcliffe TL, Gaetz WC, Logan WJ, Cheyne DO, Fehlings DL. Cortical reorganization after modified constraint-induced movement therapy in pediatric hemiplegic cerebral palsy. J Child Neurol 2007; 22 (11) 1281-1287
- 33 Yang TF, Fu CP, Kao NT, Chan RC, Chen SJ. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil 2003; 82 (04) 284-289
- 34 Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indication and outcome. Eur J Neurol 1997; 4 (Suppl. 02) S15-S22
- 35 Moleaners G, Desloovere K, Eyssen M. , et al. Botulinum toxin type A treatment of cerebral palsy: an integrated approach. Eur J Neurol 1999; 6 (Suppl. 04) S51-S57
- 36 Dai AI, Demiryürek AT. Serial casting as an adjunct to botulinum toxin type a treatment in children with cerebral palsy and spastic paraparesis with scissoring of the lower extremities. J Child Neurol 2017; 32 (07) 671-675
- 37 Bertoncelli CM, Solla F, Loughenbury PR, Tsirikos AI, Bertoncelli D, Rampal V. Risk factors for developing scoliosis in cerebral palsy: a cross-sectional descriptive study. J Child Neurol 2017; 32 (07) 657-662
- 38 Bertoncelli CM, Bertoncelli D, Elbaum L. , et al. Validation of a clinical prediction model for the development of neuromuscular scoliosis: a multinational study. Pediatr Neurol 2018; 79: 14-20